ClinicalTrials.gg
Status unknownNCT05622890Updated Nov 21, 2022

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

A Phase 3 interventional study of Mirvetuximab Soravtansine in Epithelial Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Status unknown at 28 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-21.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Carcinoma, Ovarian Epithelial with a site in China — 30 open to participants now, 37 under way, 11 of them phase 3. Carcinoma, Ovarian Epithelial · China.

Planned enrollment
39th of 53
35 · median 94
Started
2022
with 6 others
Phase 3
20 of 71
8 open now
Registered
43rd of 71
by date

Among the 71 studies in Carcinoma, Ovarian Epithelial with a site in China, this one is the 39th largest by planned enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2022, is one of 20 in phase 3, and was the 43rd registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

30 of the 71 studies in Carcinoma, Ovarian Epithelial with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carcinoma, Ovarian Epithelial with a site in China, or all of them as a file.
02

Study summary

This Phase III single-arm study is to evaluate the efficacy and safety of IMGN853 in Chinese adult patients with platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers (hereafter referred to as PROC) with high FRα expression.

Read the detailed description

This is a single-arm, phase III clinical trial of IMGN853 in Chinese adult patients with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal or fallopian tube cancer with high expression of folate receptor-α.

The objective of this study is to determine the efficacy of IMGN853 in platinum-resistant ovarian cancer (PROC) patients with high folate receptor alpha (FRα) expression.

A total of 35 patients will be enrolled. All patients must have measurable disease (per Response Evaluation Criteria in Solid Tumors version 1.1, RECIST v1.1) at baseline and be eligible for receiving IMGN853.

All patients will be treated with the IMGN853 monotherapy with a dose at adjusted ideal body weight (AIBW) of 6 mg/kg on Day 1 of every 3-week cycle (Q3W).

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Keywords

  • Platinum resistant
  • Folate-receptor alpha expression
  • Phase 3
  • Antibody-drug conjugate
  • mirvetuximab soravtansine
  • IMGN853
  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer
  • MIRV
  • FRα
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients ≥ 18 years of age
  2. Patients must have a histopathologically confirmed diagnosis of high-grade serous EOC.
  3. Patients must have platinum-resistant disease:

    1. Patients must have had a response (CR or PR) after previous 1 line of platinum-based therapy for at least 4 cycles of treatment, and then progressed between > 3 months and ≤ 6 months after the date for last dose of platinum.
    2. Patients who after > 6 months since the last platinum-based treatment with at least 4 cycles of one line platinum-based therapy: 1) continued to receive at least 4 cycles of 2 or 3 lines of platinum-based treatment and must have had PD within 6 months from the last dose of platinum; or 2) had PD during treatment with 2 or 3 lines of platinum-containing chemotherapy.

    Note: PD should be calculated from the date of the last dose of platinum-containing therapy to the date of PD indicated by radiographic imaging.

    Note: Patients who are platinum-refractory during 1 line treatment are excluded (see exclusion criterion 3).

  4. Patients must have radiological PD on or after the most recent anti-cancer therapy.
  5. Patients must be willing to provide the slides or undergo low-risk routine medical procedures to collect new biopsy samples for immunohistochemistry (IHC) confirmation of FRα positivity.
  6. Per VENTANA FOLR1 (FOLR-2.1) Assay criteria, patient's tumor must be positive for FRα expression by a central laboratory.
  7. Patients must have at least one lesion that meets the definition of by v1.1 (radiologically assessed by the investigator).
  8. Patients must have received at least 1 but no more than 3 lines of prior systemic anti-cancer therapy, including at least 1 containing bevacizumab, and for whom monotherapy is appropriate for the next line of treatment:

    1. ± adjuvant is considered as 1 line of therapy;
    2. Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered as part of the prior line of therapy (ie, not counted independently);
    3. Therapy changed due to toxicity in the absence of PD will be considered as part of the same line (ie, not counted independently);
    4. Hormonal therapy (except as maintenance therapy) will be considered as a separate line of therapy.
  9. Patients must have an Performance Status (ECOG PS) of 0 or 1.
  10. Patients must have completed prior therapy within the following specified times:

    1. Systemic anti-tumor therapy (the last prior systemic anti-tumor therapy should be at least 5 half-lives or 4 weeks from the initiation of the drug, whichever is shorter);
    2. Focal radiotherapy: previous focal radiotherapy should be at least 2 weeks from the initiation of investigational drug.
  11. All toxicities (except alopecia) associated with prior therapy must be stable or resolved (Grade 1 or normal).
  12. Any major surgery that a patient has undergone must have been completed at least 4 weeks prior to the first dose of IMGN853 and the postoperative complications of prior surgical treatment have resolved or are stable.
  13. Patients must have adequate hematologic, hepatic, and renal functions as defined by the following parameters (without G-CSF [a 20-day drug for long-acting growth factors], human albumin injection and other corrective treatment drugs are not allowed within 14 days before obtaining laboratory test values):

    1. (ANC) ≥ 1.5 × 10\^9/L (1,500 μL);
    2. count ≥ 100 × 10\^9/L (100,000/μL) without platelet transfusion in the prior 10 days;
    3. ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days;
    4. Serum creatinine ≤ 1.5 × (ULN);
    5. Both (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN;
    6. Serum ≤ 1.5 × ULN (patients with Gilbert syndrome may be enrolled if total bilirubin is \< 3.0 × ULN);
    7. Serum albumin ≥ 2 g/dL.
  14. Patients or their legally authorized representatives must be willing and able to sign the ICF and comply with the requirements of the protocol.
  15. Women of child bearing potential (WCBP), defined as a sexually mature woman who have not undergone surgical sterilization or who have not been naturally for at least 12 consecutive months (ie, who have had menses any time in the preceding 12 consecutive months) must agree to use effective methods; examples included oral, parenteral, or implantable hormonal contraceptive, intrauterine device, barrier contraceptive with spermicide, partner's latex condom or vasectomy) while on study treatment and for at least 12 weeks after the last dose of investigational drug.
  16. WCBP must have a negative pregnancy test within 4 days prior to the first dose of IMGN853.
  17. The expected survival of the subject is at least 12 weeks as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Male patients.
  2. Patients with endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, or sarcoma tissue, mixed tumor containing any of the above histologies, or low grade/borderline ovarian tumor.
  3. Patients with primary platinum- disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of platinum-containing chemotherapy.
  4. Patients who have received prior wide-field radiotherapy (RT) with at least 20% of the bone marrow affected.
  5. Patients with > Grade 1 peripheral neuropathy per (CTCAE).
  6. Patients with active or chronic corneal disorders, history of corneal transplant, or active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring treatment with intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilloedema, and /or monocular vision.
  7. Patients with serious concurrent illness or active infection, including, but not limited to the following:

    1. Known acute or chronic active (HBsAg positive and HBV DNA viral load ≥ 2500 copies/mL or > 500 IU/mL, if necessary, patients may receive nucleoside prophylactic anti-hepatitis B virus therapy) or acute or chronic active (HCV antibody positive and HCV RNA positive);
    2. (HIV) infection;
    3. Active cytomegalovirus infection;
    4. Any other concurrent infectious disease requiring systematic treatment within 2 weeks prior to the first dose of IMGN853.
  8. Patients with a history of multiple sclerosis (MS) or other demyelinating diseases and/or Lambert-Eaton syndrome (paraneoplastic syndrome).
  9. Patients with clinically significant cardiac disorders, including but not limited to any of the following:

    1. Myocardial infarction ≤ 6 months prior to the first dose;
    2. Unstable angina pectoris;
    3. Uncontrolled congestive cardiac failure ( classification > II);
    4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE criteria);
    5. Uncontrolled cardiac arrhythmias.
  10. Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to signing the ICF.
  11. Patients with a history of hepatic cirrhosis ( B or C).
  12. Patients with a previous clinical diagnosis of or currently ongoing non-infectious interstitial lung disease (ILD), including noninfectious pneumonitis, lung disorders such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pulmonitis, severely impaired lung function, etc.
  13. Patients requiring folic acid-containing supplements (e.g., folate deficiency).
  14. Known to previous monoclonal antibody therapy or maytansinoids, or to the drug and/or any .
  15. Pregnant or lactating women.
  16. Patients with prior IMGN853 or other FRα-targeted drug therapies.
  17. Known active central nervous system (CNS) and/or . Patients with untreated but asymptomatic , or patients who have radiographically documented progression-free status for at least 4 weeks after treatment and do not require hormonal or antiepileptic therapy for at least 2 weeks may be considered for enrollment.
  18. Patients with a history of other within 3 years prior to enrollment.

    Note: patients with tumors with a negligible risk of or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible for inclusion.

  19. Patients with pleural effusion, pericardial effusion, or ascites that cannot be controlled by drainage or other means, except the small amount of effusion that without clinical symptoms or do not require clinical intervention.
  20. Patients who are detained by a court or administrative decision, receiving psychiatric care against their will, adults who are under the protection of law (under tutorship/curatorship), people who are unable to give their consent, and people who are subject to a legal guardianship.
  21. Participated in other clinical studies and received their investigational drugs within 4 weeks prior to the first dose.
  22. Subject has other serious systemic diseases or other reasons that are not suitable for participation in this clinical study as evaluated by the investigator.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    treatment

    All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).

    Drug: Mirvetuximab Soravtansine

Interventions

  • Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.

    Also known as: IMGN853, MIRV

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the BIRC.

    Time frame: Up to 2 years

Secondary outcomes

  1. Duration of response (DOR)

    The time interval from initial response (CR or PR) assessed by the investigator and the BIRC to progressive disease (PD) assessed by the BIRC

    Time frame: Up to 2 years

  2. ORR assessed by the investigator

    The best response of CR or PR assessed by the investigator.

    Time frame: Up to 2 years

  3. DOR assessed by the investigator

    The time interval from initial response (CR or PR) assessed by the investigator to PD assessed by the investigator

    Time frame: Up to 2 years

  4. Treatment-emergent adverse events (TEAEs) and Laboratory results,physical examinations, or vital signs

    Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AE's will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT).

    Time frame: Up to 2 years

  5. Determination of CA-125 response with GCIG criteria

    GCIG CA-125 response rate will be calculated using the CA-125 Response-Evaluable population and its exact 95% CI will be estimated using the Clopper-Pearson method.

    Time frame: Up to 2 years

  6. PFS assessed by the BIRC

    The time interval from the first dose of IMGN853 to radiographic PD or death assessed by the BIRC, whichever occurs first.

    Time frame: Up to 2 years

  7. PFS assessed by the investigator

    The time interval from the first dose of IMGN853 to radiographic PD or death assessed by the investigator, whichever occurs first.

    Time frame: Up to 2 years

  8. Overall survival (OS)

    The time interval from the first dose of IMGN853 to death

    Time frame: Up to 2 years

  9. Summary statistics of intact ADC, total Ab (TAb), DM4 and S-methyl DM4 concentration data over time

    To assess the PK properties of IMGN853 and its key metabolites

    Time frame: Up to 2 years

  10. Incidence of seroconversion of ADA caused by IMGN853 and its relationship to safety and efficacy

    Subjects will be evaluated for anti-drug antibody (ADA) levels. Confirmatory experiments will be conducted for positive samples. ADA titers and neutralizing antibodies (Nabs) will be further determined as appropriate after the confirmation of positivity.

    Time frame: Up to 2 years

Other outcomes

  1. Relationship between test results using the companion diagnostic reagent from MEDx Translational Medicine (Suzhou) Co., Ltd. and efficacy of IMGN853 and consistency with VENTANA FOLR1

    Samples will be tested by another CDx at same time to certify the consistency with VENTANA FOLR1

    Time frame: Up to 2 years

07

Study locations

27 of 28 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
    Recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
    Recruiting
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
    Recruiting
  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University
    Beijing, Beijing 100010, China
    Not yet recruiting
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian 350000, China
    Recruiting
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730000, China
    Recruiting
  • Sun Yat-Sen University Cancer Hospital
    Guangzhou, Guangdong 510000, China
    Recruiting
  • Affiliated Cancer Hospital of Guangxi Medical University
    Nanning, Guangxi 530015, China
    Recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
    Recruiting
  • Hubei Cancer Hospital
    Wuhan, Hubei 430000, China
    Recruiting
  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technolog
    Wuhan, Hubei 430000, China
    Recruiting
  • Zhongnan Hospital Affiliated to Wuhan University
    Wuhan, Hubei 430000, China
    Recruiting
  • Hunan Cancer Hospital
    Changsha, Hunan 410000, China
    Recruiting
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330008, China
    Recruiting
  • Jilin Cancer Hospital
    Changchun, Jilin 130000, China
    Recruiting
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116000, China
    Recruiting
  • Liaoning Cancer Hospital
    Shengyang, Liaoning 110084, China
    Recruiting
  • Shandong Cancer Hospital
    Jinan, Shandong 250000, China
    Recruiting
  • Shanghai Tumor Hospital
    Shanghai, Shanghai 200000, China
    Recruiting
  • SIMC
    Shanghai, Shanghai 200000, China
    Recruiting
  • People's Hospital of Shanxi province
    Xi'an, Shanxi 710000, China
    Recruiting
  • West China Second Hospital of Sichuan University
    Chengdu, Sichuan 610000, China
    Recruiting
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650000, China
    Recruiting
  • People's Hospital of Zhejiang Province
    Hangzhou, Zhejiang 310000, China
    Recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
  • Zhejiang Tumor Hospital
    Hangzhou, Zhejiang 310000, China
    Recruiting
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
  • The Second Affiliated Hospital of Zhengzhou University
    Henan, Zhengzhou 450000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Apr 2023, 8 months after the start.

Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 21, 2022
StartActual
Aug 18, 2022
Primary completionEst.
Apr 30, 2023
CompletionEst.
Dec 31, 2023
Last update
Nov 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05622890
Responsible party
Sponsor
First posted
Nov 21, 2022
Start date
Aug 18, 2022
Primary completion
Apr 30, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Nov 21, 2022

Study contacts

Xu Sun, Master
Contact
sunxu@eastchinapharm.com
+8613645153601

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion